earnings
confidence high
sentiment positive
materiality 0.75
Atara Q2 net income $2.4M; tab-cel BLA accepted with Jan 10, 2026 PDUFA date
Atara Biotherapeutics, Inc.
2025-Q2 EPS
reported $3.49
vs consensus -$0.47
▲ beat
(+843.8%)
- Cash, equivalents and short-term investments $22.3M at June 30, up from $13.8M at March 31.
- Net income $2.4M ($0.19 diluted EPS) vs. net loss prior year; revenues $17.6M, down from $28.6M.
- FDA accepted tab-cel BLA with Priority Review; PDUFA goal date January 10, 2026.
- Completed transfer of substantially all tab-cel activities to Pierre Fabre; $40M milestone due on FDA approval.
- Full-year 2025 operating expenses expected to decrease at least 60% vs 2024; strategic options evaluation resumed.
item 2.02item 9.01